JP7300989B2 - 核酸分子を解析するための方法およびシステム - Google Patents

核酸分子を解析するための方法およびシステム Download PDF

Info

Publication number
JP7300989B2
JP7300989B2 JP2019533331A JP2019533331A JP7300989B2 JP 7300989 B2 JP7300989 B2 JP 7300989B2 JP 2019533331 A JP2019533331 A JP 2019533331A JP 2019533331 A JP2019533331 A JP 2019533331A JP 7300989 B2 JP7300989 B2 JP 7300989B2
Authority
JP
Japan
Prior art keywords
nucleic acid
dna
nucleic acids
molecules
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504606A (ja
JP2020504606A5 (enExample
Inventor
アンドリュー ケネディ，
ステファニー アン ウォード モーティマー，
ヘルミー エルトーキー，
アミルアリ タラサズ，
ダイアナ アブドゥエヴァ，
マシュー シュルツ，
Original Assignee
ガーダント ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7300989(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ガーダント ヘルス， インコーポレイテッド filed Critical ガーダント ヘルス， インコーポレイテッド
Publication of JP2020504606A publication Critical patent/JP2020504606A/ja
Publication of JP2020504606A5 publication Critical patent/JP2020504606A5/ja
Priority to JP2023060942A priority Critical patent/JP7756676B2/ja
Application granted granted Critical
Publication of JP7300989B2 publication Critical patent/JP7300989B2/ja
Priority to JP2024113220A priority patent/JP2024147684A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/101—DNA polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/107—RNA dependent DNA polymerase,(i.e. reverse transcriptase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/164—Methylation detection other then bisulfite or methylation sensitive restriction endonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/514—Detection characterised by immobilisation to a surface characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019533331A 2016-12-22 2017-12-22 核酸分子を解析するための方法およびシステム Active JP7300989B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023060942A JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662438240P 2016-12-22 2016-12-22
US62/438,240 2016-12-22
US201762512936P 2017-05-31 2017-05-31
US62/512,936 2017-05-31
US201762550540P 2017-08-25 2017-08-25
US62/550,540 2017-08-25
PCT/US2017/068329 WO2018119452A2 (en) 2016-12-22 2017-12-22 Methods and systems for analyzing nucleic acid molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060942A Division JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2020504606A JP2020504606A (ja) 2020-02-13
JP2020504606A5 JP2020504606A5 (enExample) 2021-02-04
JP7300989B2 true JP7300989B2 (ja) 2023-06-30

Family

ID=61006366

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533331A Active JP7300989B2 (ja) 2016-12-22 2017-12-22 核酸分子を解析するための方法およびシステム
JP2023060942A Active JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A Pending JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023060942A Active JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A Pending JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Country Status (11)

Country Link
US (7) US11519019B2 (enExample)
EP (1) EP3559270A2 (enExample)
JP (3) JP7300989B2 (enExample)
KR (2) KR102723226B1 (enExample)
CN (1) CN110325650A (enExample)
AU (1) AU2017382439B2 (enExample)
BR (1) BR112019012958A2 (enExample)
CA (1) CA3046007A1 (enExample)
IL (2) IL302912A (enExample)
MX (1) MX2019007444A (enExample)
WO (1) WO2018119452A2 (enExample)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
DK3246416T3 (da) 2011-04-15 2024-09-02 Univ Johns Hopkins Sikkert sekventeringssystem
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
CN110964796B (zh) 2013-08-28 2024-04-05 贝克顿迪金森公司 大规模平行单细胞分析
WO2016160844A2 (en) 2015-03-30 2016-10-06 Cellular Research, Inc. Methods and compositions for combinatorial barcoding
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
KR102638006B1 (ko) 2016-09-26 2024-02-20 셀룰러 리서치, 인크. 바코딩된 올리고뉴클레오티드 서열을 갖는 시약을 이용한 단백질 발현의 측정
US11414710B2 (en) * 2016-12-28 2022-08-16 Quest Diagnostics Investments Llc Compositions and methods for detecting circulating tumor DNA
EP3610034B1 (en) 2017-04-12 2022-06-08 Karius, Inc. Sample preparation methods, systems and compositions
EP4345172A3 (en) 2017-06-05 2024-07-03 Becton, Dickinson and Company Sample indexing for single cells
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
WO2019195268A2 (en) 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels
AU2019262048B2 (en) 2018-05-03 2025-09-04 Becton, Dickinson And Company High throughput multiomics sample analysis
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US12178549B2 (en) 2018-10-11 2024-12-31 Seno Medical Instruments, Inc. Optoacoustic image analysis method and system for automatically estimating lesion traits
AU2019351130B2 (en) 2018-09-27 2025-10-23 GRAIL, Inc Methylation markers and targeted methylation probe panel
CN118853827A (zh) 2018-10-01 2024-10-29 贝克顿迪金森公司 确定5’转录物序列
CN112969789A (zh) 2018-11-08 2021-06-15 贝克顿迪金森公司 使用随机引发的单细胞全转录组分析
EP3894552A1 (en) 2018-12-13 2021-10-20 Becton, Dickinson and Company Selective extension in single cell whole transcriptome analysis
CN113454218A (zh) * 2018-12-20 2021-09-28 夸登特健康公司 用于改进核酸分子的回收的方法、组合物和系统
EP3914728B1 (en) 2019-01-23 2023-04-05 Becton, Dickinson and Company Oligonucleotides associated with antibodies
AU2020212057A1 (en) * 2019-01-25 2021-08-26 GRAIL, Inc Detecting cancer, cancer tissue of origin, and/or a cancer cell type
EP3918089B1 (en) 2019-01-31 2025-01-15 Guardant Health, Inc. Method for isolating and sequencing cell-free dna
CN113454234B (zh) 2019-02-14 2025-03-18 贝克顿迪金森公司 杂合体靶向和全转录物组扩增
WO2020176659A1 (en) 2019-02-27 2020-09-03 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free dna
WO2020229437A1 (en) * 2019-05-14 2020-11-19 F. Hoffmann-La Roche Ag Devices and methods for sample analysis
EP3976822A1 (en) 2019-05-31 2022-04-06 Guardant Health, Inc. Methods and systems for improving patient monitoring after surgery
EP4004231B1 (en) 2019-07-22 2025-11-12 Becton, Dickinson and Company Single cell chromatin immunoprecipitation sequencing assay
JP7323703B2 (ja) * 2019-08-19 2023-08-08 エフ． ホフマン－ラ ロシュ アーゲー 配列決定用のｄｎａ及びｒｎａのシングルチューブ調製
WO2021067484A1 (en) 2019-09-30 2021-04-08 Guardant Health, Inc. Compositions and methods for analyzing cell-free dna in methylation partitioning assays
CN114729350A (zh) 2019-11-08 2022-07-08 贝克顿迪金森公司 使用随机引发获得用于免疫组库测序的全长v(d)j信息
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
ES3031713T3 (en) * 2019-11-26 2025-07-10 Guardant Health Inc Methods, compositions and systems for improving the binding of methylated polynucleotides
WO2021127208A1 (en) * 2019-12-20 2021-06-24 Accuragen Holdings Limited Methods and systems for disease detection
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
GB202000747D0 (en) * 2020-01-17 2020-03-04 Institute Of Cancer Res Monitoring tumour evolution
EP4097228B1 (en) 2020-01-29 2024-08-14 Becton, Dickinson and Company Barcoded wells for spatial mapping of single cells through sequencing
CN115516108A (zh) 2020-02-14 2022-12-23 约翰斯霍普金斯大学 评估核酸的方法和材料
WO2021173719A1 (en) 2020-02-25 2021-09-02 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
US20210285042A1 (en) * 2020-02-28 2021-09-16 Grail, Inc. Systems and methods for calling variants using methylation sequencing data
WO2021202752A1 (en) * 2020-03-31 2021-10-07 Guardant Health, Inc. Determining tumor fraction for a sample based on methyl binding domain calibration data
WO2021222828A1 (en) 2020-04-30 2021-11-04 Guardant Health, Inc. Methods for sequence determination using partitioned nucleic acids
EP4150117A4 (en) * 2020-05-12 2024-05-29 The Board of Trustees of the Leland Stanford Junior University SYSTEM AND METHOD FOR GENE EXPRESSION AND SOURCE TISSUE INFRINGEMENT FROM CELL-FREE DNA
WO2021231455A1 (en) * 2020-05-13 2021-11-18 Accuragen Holdings Limited Cell-free dna size detection
EP4150118A1 (en) 2020-05-14 2023-03-22 Becton Dickinson and Company Primers for immune repertoire profiling
US12241126B2 (en) 2020-05-14 2025-03-04 Guardant Health, Inc. Homologous recombination repair deficiency detection
US12467096B2 (en) 2020-05-15 2025-11-11 Universal Diagnostics, S.A. Methods and systems for identifying methylation biomarkers
AU2021276524A1 (en) 2020-05-22 2023-01-05 Aqtual, Inc. Methods for characterizing cell-free nucleic acid fragments
EP4407030B1 (en) 2020-06-02 2025-12-17 Becton, Dickinson and Company Oligonucleotides and beads for 5 prime gene expression assay
WO2022002424A1 (en) 2020-06-30 2022-01-06 Universal Diagnostics, S.L. Systems and methods for detection of multiple cancer types
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4179111B1 (en) 2020-07-10 2024-04-03 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
CN111826430A (zh) * 2020-07-24 2020-10-27 扬州大学 一种研究鸡PGCs中lncRNA和组蛋白甲基化酶共调控靶基因的方法
EP4585697A3 (en) 2020-07-30 2025-08-06 Guardant Health, Inc. Methods for isolating cell-free dna
CN116194589A (zh) 2020-07-31 2023-05-30 贝克顿迪金森公司 用于转座酶可及染色质的单细胞测定
WO2022040147A1 (en) * 2020-08-19 2022-02-24 Accuragen Holdings Limited Methods for selective cell-free nucleic acid analysis
JP2023540221A (ja) 2020-08-25 2023-09-22 ガーダント ヘルス， インコーポレイテッド バリアントの起源を予測するための方法およびシステム
US20220162670A1 (en) * 2020-09-30 2022-05-26 Guardant Health, Inc. Methods and systems to improve the signal to noise ratio of dna methylation partitioning assays
CA3195797A1 (en) 2020-10-23 2022-04-28 Andrew Kennedy Compositions and methods for analyzing dna using partitioning and base conversion
WO2022108946A1 (en) 2020-11-17 2022-05-27 Becton, Dickinson And Company Combined analysis of cell-free nucleic acids and single cells for oncology diagnostics
WO2022109343A1 (en) 2020-11-20 2022-05-27 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
CA3199829A1 (en) 2020-11-30 2022-06-02 Guardant Health, Inc. Compositions and methods for enriching methylated polynucleotides
US12392771B2 (en) 2020-12-15 2025-08-19 Becton, Dickinson And Company Single cell secretome analysis
WO2022140629A1 (en) * 2020-12-23 2022-06-30 Guardant Health, Inc. Methods and systems for analyzing methylated polynucleotides
EP4291679A1 (en) 2021-02-12 2023-12-20 Guardant Health, Inc. Methods and compositions for detecting nucleic acid variants
WO2022187867A1 (en) * 2021-03-05 2022-09-09 The Trustees Of Columbia University In The City Of New York Methods to analyze methylomes in tumor and plasma cell-free dna
EP4302301A1 (en) 2021-03-05 2024-01-10 Guardant Health, Inc. Methods and related aspects for analyzing molecular response
WO2022192189A1 (en) * 2021-03-09 2022-09-15 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
EP4305200A1 (en) 2021-03-09 2024-01-17 Guardant Health, Inc. Detecting the presence of a tumor based on off-target polynucleotide sequencing data
WO2022204730A1 (en) 2021-03-25 2022-09-29 Guardant Health, Inc. Methods and compositions for quantifying immune cell dna
EP4314340A4 (en) * 2021-03-30 2024-11-27 Resolution Bioscience, Inc. COMPOSITIONS AND METHODS FOR SIMULTANEOUS GENETIC ANALYSIS OF MULTIPLE LIBRARIES
EP4326906A4 (en) * 2021-04-23 2025-03-12 The Translational Genomics Research Institute Analysis of fragment ends in dna
WO2022251655A1 (en) 2021-05-28 2022-12-01 Guardant Health, Inc. Compositions and methods for assaying circulating molecules
EP4359562A1 (en) 2021-06-21 2024-05-01 Guardant Health, Inc. Methods and compositions for copy-number informed tissue-of-origin analysis
US20250283170A1 (en) * 2021-07-12 2025-09-11 The Trustees Of The University Of Pennsylvania Modified adapters for enzymatic dna deamination and methods of use thereof for epigenetic sequencing of free and immobilized dna
WO2023056065A1 (en) 2021-09-30 2023-04-06 Guardant Health, Inc. Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
EP4426858A2 (en) 2021-11-02 2024-09-11 Guardant Health, Inc. Quality control method
EP4430396A1 (en) 2021-11-12 2024-09-18 Guardant Health, Inc. Method of analysis of methylated dna-binding proteins
WO2023122623A1 (en) 2021-12-21 2023-06-29 Guardant Health, Inc. Methods and systems for combinatorial chromatin-ip sequencing
WO2023122740A1 (en) 2021-12-23 2023-06-29 Guardant Health, Inc. Compositions and methods for detection of metastasis
WO2023147568A2 (en) * 2022-01-28 2023-08-03 Flagship Pioneering Innovations Vi, Llc Compositions and methods for making and using an immortalized library
JP2025513786A (ja) 2022-04-07 2025-04-30 ガーダント ヘルス， インコーポレイテッド 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出
EP4547857A1 (en) 2022-06-30 2025-05-07 Guardant Health, Inc. Enrichment of aberrantly methylated dna
JP2025523964A (ja) 2022-07-21 2025-07-25 ガーダント ヘルス， インコーポレイテッド 試料調製により誘発されるメチル化アーチファクトの検出および低減のための方法
WO2024040006A2 (en) * 2022-08-15 2024-02-22 Bioscreening & Diagnostics Llc Ai and ml-based system to predict cancer from epigenetic data
WO2024059840A1 (en) 2022-09-16 2024-03-21 Guardant Health, Inc. Compositions and methods for analyzing soluble proteins
WO2024073508A2 (en) 2022-09-27 2024-04-04 Guardant Health, Inc. Methods and compositions for quantifying immune cell dna
KR20250110272A (ko) 2022-11-15 2025-07-18 가던트 헬쓰, 인크. 순환 종양 dna (ctdna)로부터 기준선 ctdna 수준 및 시간 경과에 따른 ctdna 수준의 종단적 변화 둘 다로부터의 신호를 이용하여 비소세포 폐암 (nsclc) 환자 약물 반응 또는 사망 또는 암 진행까지의 시간을 예측하는 방법
CN120569782A (zh) 2022-12-21 2025-08-29 夸登特健康公司 基于无细胞核酸分子的甲基化状态检测同源重组缺陷
WO2024137880A2 (en) 2022-12-22 2024-06-27 Guardant Health, Inc. Methods involving methylation preserving amplification with error correction
EP4638782A2 (en) 2022-12-22 2025-10-29 Guardant Health, Inc. Integrated targeted and whole genome somatic and dna methylation sequencing workflows
EP4649489A1 (en) 2023-01-11 2025-11-19 Guardant Health, Inc. Joint modeling of longitudinal and time-to-event data to predict patient survival
EP4655416A1 (en) 2023-01-25 2025-12-03 Guardant Health, Inc. Nucleic acid methylation profiling method
WO2024186768A1 (en) * 2023-03-07 2024-09-12 Guardant Health, Inc. Hybrid ssdna- and dsdna-ngs library preparation methods
US20250101522A1 (en) 2023-04-12 2025-03-27 Guardant Health, Inc. Brca1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
WO2024229143A1 (en) 2023-05-01 2024-11-07 Guardant Health, Inc. Quality control method for enzymatic conversion procedures
WO2024229433A1 (en) 2023-05-03 2024-11-07 Guardant Health, Inc. Methods for analysis of dna methylation
WO2024233502A1 (en) 2023-05-05 2024-11-14 Guardant Health, Inc. Cell-free dna blood-based test for cancer screening
US20240420800A1 (en) 2023-06-15 2024-12-19 Guardant Health, Inc. METHOD FOR HRD DETECTION IN TARGETED cfDNA SAMPLES USING DE NOVO MUTATIONAL SIGNATURES
WO2024264065A1 (en) 2023-06-23 2024-12-26 Guardant Health, Inc. Methods and compositions for quantifying immune cell nucleic acids
WO2025007034A1 (en) 2023-06-29 2025-01-02 Guardant Health, Inc. Methods for determining surveillance and therapy for diseases
WO2025007038A1 (en) 2023-06-30 2025-01-02 Guardant Health, Inc. Methods for early detection of cancer
WO2025019297A1 (en) 2023-07-14 2025-01-23 Guardant Health, Inc. Classification of colorectal tumors using dna methylation from liquid biopsy
WO2025019370A1 (en) * 2023-07-14 2025-01-23 Natera, Inc. Methods for assaying circulating tumor dna
WO2025019254A1 (en) 2023-07-14 2025-01-23 Guardant Health, Inc. Classification of breast tumors using dna methylation from liquid biopsy
WO2025024497A1 (en) 2023-07-24 2025-01-30 Guardant Health, Inc. Significance modeling of clonal-level target variants using methylation detection
WO2025029645A1 (en) 2023-07-28 2025-02-06 Guardant Health, Inc. Methods and systems for identifying an origin of a variant
WO2025029475A1 (en) 2023-07-28 2025-02-06 Guardant Health, Inc. Methods to enrich nucleotide variants by negative selection
US20250218587A1 (en) 2023-07-31 2025-07-03 Guardant Health, Inc. Methods and systems for identifying tumor origin
WO2025038399A1 (en) 2023-08-11 2025-02-20 Guardant Health, Inc. Methylated enrichment methods for single-molecule genetic and epigenetic sequencing
US20250084469A1 (en) 2023-09-12 2025-03-13 Guardant Health, Inc. Methods for analyzing nucleic acids using sequence read family size distribution
WO2025064706A1 (en) 2023-09-19 2025-03-27 Guardant Health, Inc. Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025064489A1 (en) 2023-09-20 2025-03-27 Guardant Health, Inc. Systems and methods for real world evidence database data integration
WO2025072084A1 (en) * 2023-09-25 2025-04-03 Foundation Medicine, Inc. Updating records based on consensus annotations of genetic variants
WO2025072467A1 (en) 2023-09-29 2025-04-03 Guardant Health, Inc. Genotyping cyp2d6
WO2025076425A1 (en) 2023-10-06 2025-04-10 Guardant Health, Inc. Genomic and methylation biomarkers for prediction of copy number loss / gene deletion
WO2025085784A1 (en) 2023-10-18 2025-04-24 Guardant Health, Inc. Genomic and methylation biomarkers for determining patient risk of heart disease and novel genomic and epigenomic drug targets to decrease risk of heart disease and/or improve patient outcome after myocardial infarction or cardiac injury
WO2025090954A1 (en) 2023-10-26 2025-05-01 Guardant Health, Inc. Methods for detecting nucleic acid variants
WO2025090956A1 (en) 2023-10-26 2025-05-01 Guardant Health, Inc. Methods for detecting nucleic acid variants using capture probes
WO2025106796A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Non-small cell lung cancer (nsclc) histology classification using dna methylation data captured from liquid biopsies
WO2025106263A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Joint modeling of longitudinal and time-to-event data to predict patient survival
WO2025106837A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Tumor fraction and outcome association in a real-world non-small cell lung cancer (nsclc) cohort using a methylation-based circulating tumor dna (ctdna) assay
US20250243550A1 (en) 2023-11-15 2025-07-31 Guardant Health, Inc. Minimum residual disease (mrd) detection in early stage cancer using urine
WO2025137620A1 (en) 2023-12-21 2025-06-26 Guardant Health, Inc. Methods for high quality and high accuracy methylation sequencing
WO2025160433A1 (en) 2024-01-24 2025-07-31 Guardant Health, Inc. Methods for analyzing sequencing reads
WO2025207817A1 (en) 2024-03-26 2025-10-02 Guardant Health, Inc. Method of determining the likelihood of a disease by combining biomarkers and imaging
WO2025207788A1 (en) 2024-03-27 2025-10-02 Guardant Health, Inc. Inferring cnvs from the distribution of molecules in hyper partition
WO2025207921A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for methylation enrichment using cpg-specific deamination
WO2025208044A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for cancer detection using molecular patterns
WO2025212664A1 (en) 2024-04-01 2025-10-09 Guardant Health, Inc. Small variant calling with error-rate based model
WO2025235602A1 (en) 2024-05-07 2025-11-13 Guardant Health, Inc. Predictive, prognostic signatures for immuno-oncology using liquid biopsy
WO2025235889A1 (en) 2024-05-10 2025-11-13 Guardant Health, Inc. Methods involving multiplexed pooled pcr
WO2025245433A1 (en) 2024-05-23 2025-11-27 Guardant Health, Inc. Generalized probabilistic generative modeling method for analysis of tumor methylated molecules in target capture regions
WO2025250544A1 (en) 2024-05-31 2025-12-04 Guardant Health, Inc. Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna
US12467087B1 (en) 2024-06-25 2025-11-11 Guardant Health, Inc. Sequencing methods with partitioning

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159292A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2016115530A1 (en) 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20030017081A1 (en) 1994-02-10 2003-01-23 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
AU2002359522A1 (en) 2001-11-28 2003-06-10 Applera Corporation Compositions and methods of selective nucleic acid isolation
US8962247B2 (en) * 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US9115386B2 (en) * 2008-09-26 2015-08-25 Children's Medical Center Corporation Selective oxidation of 5-methylcytosine by TET-family proteins
US20130157266A1 (en) * 2009-03-15 2013-06-20 Ribomed Biotechnologies, Inc. Abscription based molecular detection of dna methylation
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
HUE039766T2 (hu) 2010-10-22 2019-02-28 Cold Spring Harbor Laboratory Nukleinsavak változatainak megszámlálása genom kópiaszám információ megszerzésére
EP3904533B1 (en) * 2011-12-13 2025-02-26 Oslo Universitetssykehus HF Method for detection of hydroxymethylation status
EP4234713A3 (en) * 2012-03-20 2024-02-14 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
ES2693349T3 (es) * 2012-06-06 2018-12-11 The Trustees Of Princeton University Aplicación de códigos de barras de ADN de bancos de matrices de cromatinas y mononucleosomas diseñadores para la creación de perfiles de lectores, escritores, borradores y moduladores de cromatina de los mismos
EP2872648B1 (en) 2012-07-13 2019-09-04 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
KR102393608B1 (ko) * 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
WO2014152155A1 (en) 2013-03-14 2014-09-25 The Broad Institute, Inc. Massively multiplexed rna sequencing
US20160047001A1 (en) * 2013-04-08 2016-02-18 Carmel-Haifa University Economic Corporation Ltd. Sept4/ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS
EP2805769A1 (en) * 2013-05-24 2014-11-26 European Molecular Biology Laboratory Methods for nano-scale single cell analysis
EP4227947A1 (en) 2013-10-21 2023-08-16 Verinata Health, Inc. Method for improving the sensitivity of detection in determining copy number variations
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
EP3191628B1 (en) 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US10844428B2 (en) * 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
EP4488686A3 (en) 2016-04-14 2025-04-30 Guardant Health, Inc. Methods for early detection of cancer
US11702702B2 (en) * 2016-04-15 2023-07-18 Predicine, Inc. Systems and methods for detecting genetic alterations
JP2019515674A (ja) * 2016-04-19 2019-06-13 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝的解析および他の適用のための固定化ベースのシステムおよび方法
CA3022606A1 (en) 2016-05-03 2017-11-09 University Health Network Methods of capturing cell-free methylated dna and uses of same
EP4257701A3 (en) * 2016-06-30 2023-12-20 Grail, LLC Differential tagging of rna for preparation of a cell-free dna/rna sequencing library
JP7448310B2 (ja) 2016-07-06 2024-03-12 ガーダント ヘルス， インコーポレイテッド セルフリー核酸のフラグメントームプロファイリングのための方法
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
EP3652741A4 (en) 2017-07-12 2021-04-21 University Health Network DETECTION AND CLASSIFICATION OF CANCER USING METHYLOMA ANALYSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159292A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2016115530A1 (en) 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Applications in Plant Sciences，2014年，Vol. 2: 1400064，p. 1-6
Genome Research，2010年，Vol. 20，p. 1719-1729

Also Published As

Publication number Publication date
BR112019012958A2 (pt) 2019-11-26
IL267424A (en) 2019-08-29
US20240409979A1 (en) 2024-12-12
EP3559270A2 (en) 2019-10-30
US20240279714A1 (en) 2024-08-22
CN110325650A (zh) 2019-10-11
US20190390253A1 (en) 2019-12-26
AU2017382439A1 (en) 2019-06-20
US20240409980A1 (en) 2024-12-12
US11952616B2 (en) 2024-04-09
JP2024147684A (ja) 2024-10-16
US11519019B2 (en) 2022-12-06
US20230332206A1 (en) 2023-10-19
WO2018119452A2 (en) 2018-06-28
KR20190095410A (ko) 2019-08-14
US12428670B2 (en) 2025-09-30
US20250154558A1 (en) 2025-05-15
JP2020504606A (ja) 2020-02-13
JP2023089062A (ja) 2023-06-27
IL302912A (en) 2023-07-01
JP7756676B2 (ja) 2025-10-20
US12359245B2 (en) 2025-07-15
US20250171826A1 (en) 2025-05-29
KR20240158369A (ko) 2024-11-04
KR102723226B1 (ko) 2024-10-30
CA3046007A1 (en) 2018-06-28
WO2018119452A3 (en) 2018-08-09
US12312634B2 (en) 2025-05-27
MX2019007444A (es) 2019-08-16
AU2017382439B2 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
JP7756676B2 (ja) 核酸分子を解析するための方法およびシステム
JP7573536B2 (ja) 無細胞ｄｎａを単離するための組成物および方法
JP2024056984A (ja) エピジェネティック区画アッセイを較正するための方法、組成物およびシステム
JP2024523401A (ja) コピー数情報に基づく組織起源分析のための方法および組成物
JP2023524681A (ja) 分配された核酸を使用した配列決定のための方法
US20250308629A1 (en) Small variant calling with error-rate based model
US20250308636A1 (en) Inferring cnvs from the distribution of molecules in hyper partition
US20250201344A1 (en) Methods and systems for identifying an origin of a variant
US20250218587A1 (en) Methods and systems for identifying tumor origin
US20250243550A1 (en) Minimum residual disease (mrd) detection in early stage cancer using urine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230620

R150 Certificate of patent or registration of utility model

Ref document number: 7300989

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150